Bioxytran, Inc. Joins The Stock Day Podcast to Discuss The Commercialization of Their Stroke Treatment

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Phoenix, Arizona--(Newsfile Corp. - December 3, 2019) - The Stock Day Podcast welcomed Bioxytran, Inc. (OTCQB: BIXT) ("the Company"), a developmental stage biotechnology company. CEO of the Company, Dr. David Platt, joined Stock Day host Everett Jolly.

To begin the interview, Platt shared some background information about the Company. "The company is situated in Boston, and deals with hypoxia," explained Platt, adding that the Company develops treatments for this condition, which involves a lack of oxygen. "We're trying to solve the problem by getting the chemistry to deliver the oxygen to the tissue," said Platt. "This is a problem that is an underlying condition in many diseases," he added.

Jolly then asked about the Company's treatment method for hypoxia. Platt explained that the Company is developing a treatment involving BXT-25, which is designed to reverse hypoxia in the brain. He further explained that this treatment method can be used as a resuscitative agent for patients suffering from strokes, and may also be beneficial in treating brain injuries. "Hypoxia is a condition where you don't have oxygen, so our company is basically trying to find a way to supply the oxygen or reverse the hypoxic conditions," said Platt.

The conversation then turned to the Company's monetization strategy. Platt shared that the treatment method is a product designed to overcome the blockages that may stop red blood cells from reaching the brain. "We have developed a molecule that is 5,000 times smaller than red blood cells," explained Platt, adding that the molecule is able to penetrate blockages to allow oxygen through. "When a patient has a stroke, you inject the molecule (BXT-25) through an IV," said Platt, adding that the injection must be given to the patient soon after the stroke occurs. He further explained that upon receiving the injection, the patient could experience improved oxygen delivery for up to ten hours.

"How far away are we from commercializing this product?" asked Jolly. Platt explained that the Company has an exclusive license for a device that monitors oxygen levels in biological tissue. This device has already been through clinical trials and is approved by the FDA. After the safety of the BXT-25 substance will be confirmed, the Company will be able to utilize this device to measure its effectiveness in delivering oxygen to tissue. Platt then added that the Company expects to reach this step within the next two years.

At the close of the interview, Platt shared that the Company's major inflection points include advanced tissue engineering in combination with the BXT-25 product. Platt shared that the Company will also be working to complete clinical trials and finalize an IND application. However, Platt explained that one of the most important inflection points will be to prove to the FDA that the molecule they have developed is successful in increasing oxygen in human tissue.

Platt closed the interview by sharing that the Company is building on the work of years of extensive research in this space to become the leaders in the hypoxia treatment industry.

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at

About Bioxytran, Inc.

Bioxytran Inc. is a developmental stage biotechnology company. The company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain. Hypoxic brain injuries such as ischemic strokes, could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. To learn more, visit our website:

Resources Unlimited NW LLC

Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

Stock Day Media

To view the source version of this press release, please visit

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).